Anti-obesity drugs are showing promise for a growing list of conditions. In The Wall Street Journal, AACE President Scott D. Isaacs, MD, FACP, FACE, discusses the expanding role of GLP-1 medications in treating obesity, diabetes, and a fatty-liver condition called metabolic dysfunction-associated steatohepatitis (MASH), which affects an estimated 15 million Americans. The article also highlights broader research into the use of GLP-1s for heart and kidney disease, sleep apnea, and even Alzheimer’s.